BIOMARIN PHARMACEUTICAL INC. for BIOMARIN PHARMACEUTICAL INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2026 | $340,000 | Replaced |
| 2nd Quarter - Amendment | Jul 20, 2026 | $340,000 | Replaced |
| 2nd Quarter - Amendment | Jul 20, 2026 | $340,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN EDWARD GREISSING | — |
| KATHRYN LOWELL | — |
| DANIEL MAYNE New | SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024) |
Medicare/Medicaid MMM
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN EDWARD GREISSING | — |
| KATHRYN LOWELL | — |
| DANIEL MAYNE New | SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024) |
Tariff (miscellaneous tariff bills) TAR
GENERAL DISCUSSIONS REGARDING TARDE
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN LOWELL | — |
Medical/Disease Research/Clinical Labs MED
GENERAL DISCUSSIONS REGARDING CLINICAL TRIAL MODERNIZATION
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL MAYNE New | SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.